

11. A kit comprising: (i) a first component comprising, as an active agent, one or more unit dosage forms of vemurafenib, or a pharmaceutically-acceptable salt thereof; and (ii) a second component which comprises, as an active agent, one or more unit dosage forms of Compound III of the formula



, or a pharmaceutically acceptable salt thereof.

12. A kit according to claim ~~12~~11, for use in the treatment of a proliferative disorder, preferably cancer selected from the group consisting of colorectal cancer, melanoma, sarcoma and thyroid cancer and wherein said cancer involves a tumor comprising b-Raf having the V600E mutation.

13. The use of vemurafenib, or a pharmaceutically-acceptable salt thereof, and an MDM2 inhibitor which is Compound (III) of the formula



, or a pharmaceutically-acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer, wherein said cancer is selected from the group consisting of colorectal cancer, melanoma, sarcoma and thyroid cancer and wherein said cancer involves a tumor comprising b-Raf having the V600E mutation.